


Figure S1: Overall survival from the whole cohort (n=69) stratified by European LeukemiaNet 2017 risk classification (A), European LeukemiaNet 2022 risk classification (B), presence of more than 3 oncogenic/likely oncogenic mutations (C), presence of more than 4 variants, including those of unknown significance, likely oncogenic and oncogenic variants (D). Last plot (E) shows overall survival of 65 patients (excludes the patients with AML with *NUP98* rearrangements (n=3) and the patient with AML with *TP53* mutation, n=1) stratified by the presence of more than one mutation (only oncogenic/likely oncogenic variants) affecting *ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, ZSRS2* or *U2AF1*.